文献速递哮喘

生物标志物预测奥马珠单抗治疗成人重症哮喘的临床疗效:SoMOSA研究结果

Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

SoMOSA是一项为期1年的开放标签研究,纳入216例重症未控制特应性哮喘患者,评估奥马珠单抗治疗1年内的临床改善。191例完成第一阶段,63%早期改善;173例完成第二阶段,69% exacerbations减少≥50%,57%口服激素剂量减少≥50%。传统生物标志物未预测疗效,而5种挥发性有机化合物和5种血浆脂质生物标志物能强预测 exacerbations减少≥50%和早期反应。

要点

  • 传统生物标志物(血/痰嗜酸性粒细胞、呼出气一氧化氮、血清IgE)未预测奥马珠单抗疗效。
  • 5种挥发性有机化合物和5种血浆脂质生物标志物强预测 exacerbations减少≥50%。
  • 早期反应和晚期反应均可由上述组学标志物预测,AUC分别为0.835/0.949和0.780/0.922。

核心结论

  • 首次发现组学生物标志物可预测生物制剂治疗哮喘的改善,值得前瞻性验证和临床开发。

研究设计与样本

  • 为期1年开放标签研究(SoMOSA),纳入216例重症未控制特应性哮喘患者,分0-16周早期临床改善评估和16-52周晚期反应评估两阶段。

主要发现

  • 191例完成第一阶段,63%早期改善;173例完成第二阶段,69% exacerbations减少≥50%,57%(37/65)口服激素剂量减少≥50%。
  • 主要结局2,3-dinor-11-β-PGF2α、GETE评分和标准临床生物标志物未预测临床反应。
  • 5种挥发性有机化合物和5种血浆脂质生物标志物强预测 exacerbations减少≥50%,AUC分别为0.780和0.922。
  • 上述标志物也强预测早期反应,AUC分别为0.835和0.949。
  • 在独立队列中,气相色谱/质谱生物标志物可区分重症与轻度哮喘。

临床怎么用

  • 传统生物标志物不适用于预测奥马珠单抗疗效,组学标志物有望指导患者选择但需前瞻性验证。

局限性

  • 研究为开放标签设计,组学标志物需前瞻性验证和临床开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The anti-IgE monoclonal antibody omalizumab is widely used for severe asthma. This study aimed to identify biomarkers that predict clinical improvement during 1 year of omalizumab treatment. Methods: One-year open-label Study of Mechanisms of action of Omalizumab in Severe Asthma (SoMOSA) involving 216 patients with severe (Global Initiative for Asthma step 4/5) uncontrolled atopic asthma (at least two severe exacerbations in the previous year) taking high-dose inhaled corticosteroids and long-acting β-agonists with or without maintenance oral corticosteroids. It had two phases: 0-16 weeks, to assess early clinical improvement by Global Evaluation of Therapeutic Effectiveness (GETE); and 16-52 weeks, to assess late responses based on ⩾50% reduction in exacerbations or mOCS dose. All participants provided samples (exhaled breath, blood, sputum, urine) before and after 16 weeks of omalizumab treatment. Measurements and Main Results: A total of 191 patients completed phase 1; 63% had early improvement. Of 173 who completed phase 2, 69% had reduced exacerbations by ⩾50% and 57% (37 of 65) taking mOCSs had reduced their dose by ⩾50%. The primary outcomes 2,3-dinor-11-β-PGF2α, GETE score, and standard clinical biomarkers (blood and sputum eosinophils, exhaled nitric oxide, serum IgE) did not predict either clinical response. Five volatile organic compounds and five plasma lipid biomarkers strongly predicted the ⩾50% reduction in exacerbations (receiver operating characteristic areas under the curve of 0.780 and 0.922, respectively) and early responses (areas under the curve of 0.835 and 0.949, respectively). In an independent cohort, gas chromatography/mass spectrometry biomarkers differentiated between severe and mild asthma. Conclusions: This is the first discovery of omics biomarkers that predict improvement in asthma with biologic agent treatment. Prospective validation and development for clinical use is justified.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Djukanović R, Brinkman P, Kolmert J, et al. Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study. Am J Respir Crit Care Med. 2024. PMID: 38635834. doi:10.1164/rccm.202310-1730OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。